ArticleJournal of pain research2026
FiRST Screening Positivity Among Patients Attending a Tertiary Chronic Pain service in Oman.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To estimate the Fibromyalgia Rapid Screening Tool (FiRST) screening positivity and its sociodemographic associations among adults attending a tertiary chronic pain service in Oman. Methods: This cross-sectional study recruited 401 adults with chronic pain at the Royal Hospital in Muscat between January 2023 and January 2025. Participants completed the six-item Arabic-Egyptian FiRST; scores ≥5/6 defined as positive screening. Descriptive statistics were used to summarize participant characteristics. Bivariate analyses used Pearson's chi-square test, with crude odds ratios (ORs) and 95% confidence intervals (CIs) for categorical predictors. Variables with P < 0.20 in bivariate analyses and clinically relevant variables selected a priori were included in the multivariable logistic regression. Adjusted ORs with 95% CIs were reported for the results. Results: Overall, 170/401 participants screened positive (42.4%; exact 95% confidence interval [CI] 37.5-47.4%). Female sex was associated with higher adjusted odds (OR 1.723, 95% CI 1.065-2.787; P=0.027), while participants aged 40-59 years had lower adjusted odds than those aged 18-39 years (OR 0.528, 95% CI 0.317-0.879; P=0.014). The estimate for participants aged ≥60 years was imprecise and not statistically significant (OR 0.535, 95% CI 0.273-1.049; P=0.069). Family relationships, marital status, and academic level were not significantly associated with screening positivity after adjustment. Conclusion: FiRST screening positivity was common in this tertiary pain population in Oman. Female sex and age 40-59 years compared with 18-39 years were associated with screening positive. A positive FiRST screen requires further clinical assessment and does not establish fibromyalgia, central sensitization, or central pain syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.